You can buy or sell Vermillion and other stocks, options, ETFs, and crypto commission-free!
Vermillion, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Read More The company's bio-analytical solutions helps physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion was founded on December 9, 1993 and is headquartered in Austin, TX.
52 Week High
52 Week Low
Yahoo FinanceMay 14
Vermillion: 1Q Earnings Snapshot
AUSTIN, Texas (AP) _ Vermillion Inc. (VRML) on Tuesday reported a loss of $3.7 million in its first quarter. The Austin, Texas-based company said it had a loss of 5 cents per share. The diagnostic and bio-analytical company posted revenue of $803,000 in the period. Scroll to continue with content Ad In the final minutes of trading on Tuesday, the company's shares hit $1.34. A year ago, they were trading at $1.27. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) us...
Yahoo FinanceMay 14
Vermillion, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Vermillion, Inc. (NASDAQ: VRML) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern Time. To listen to the event live or access a replay of the call - visit https://www.investornetwork.com/company/C-8AEE4ED6C711E To receive updates for this company you can register by emailing email@example.com or by clicking get investment info from the company's profile. Scroll to continue with con...
Yahoo FinanceMay 13
Vermillion Announces Acceptance of Publication Ethnic Disparity Data Showing OVA1® Superiority over CA125 and HE4 in Detecting Ovarian Cancer Risk
Data showing detection improvements across all populations, with marked improvement in detecting ovarian malignancy risk in the African American population Findings to be published in Biomarkers in Cancer AUSTIN, Texas, May 13, 2019 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bioanalytical-based women’s health company focused on gynecologic disease, today announced acceptance of a paper entitled: “Multivariate Index Assay is Superior to CA125 and HE4 Testing in Detection of Ovarian Malignancy in Afri...
-$0.05 per share